NO20054292L - Fremgangsmate for behandling av smerte ved administrering av en nervevekstfaktorantagonist og NSAID og preparat inneholdende dette - Google Patents
Fremgangsmate for behandling av smerte ved administrering av en nervevekstfaktorantagonist og NSAID og preparat inneholdende detteInfo
- Publication number
- NO20054292L NO20054292L NO20054292A NO20054292A NO20054292L NO 20054292 L NO20054292 L NO 20054292L NO 20054292 A NO20054292 A NO 20054292A NO 20054292 A NO20054292 A NO 20054292A NO 20054292 L NO20054292 L NO 20054292L
- Authority
- NO
- Norway
- Prior art keywords
- growth factor
- nerve growth
- factor antagonist
- nsaids
- administration
- Prior art date
Links
- 229940122467 Nerve growth factor antagonist Drugs 0.000 title abstract 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 title abstract 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
Foreliggende oppfinnelse omfatter fremgangsmåter for behandling eller forebyggelse av smerte som omfatter tilførsel av en mengde av en nervevekstfaktorantagonist (for eksempel et anti-NGF-antistoff) og en mengde av en NSAID, slik at disse sammen gir effektiv smertelindring. Oppfinnelsen omfatter også preparater som omfatter en nervevekstfaktorantagonist og en NSAID, samt sett som inneholder disse.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44882303P | 2003-02-19 | 2003-02-19 | |
US44885303P | 2003-02-19 | 2003-02-19 | |
PCT/US2004/005162 WO2004073653A2 (en) | 2003-02-19 | 2004-02-19 | Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20054292L true NO20054292L (no) | 2005-09-16 |
Family
ID=32912311
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20054292A NO20054292L (no) | 2003-02-19 | 2005-09-16 | Fremgangsmate for behandling av smerte ved administrering av en nervevekstfaktorantagonist og NSAID og preparat inneholdende dette |
Country Status (16)
Country | Link |
---|---|
US (2) | US7655231B2 (no) |
EP (2) | EP2191846A1 (no) |
JP (1) | JP2006525960A (no) |
KR (1) | KR20050111598A (no) |
AT (1) | ATE491444T1 (no) |
AU (1) | AU2004213044A1 (no) |
BR (1) | BRPI0407375A (no) |
CA (1) | CA2516454A1 (no) |
DE (1) | DE602004030535D1 (no) |
EA (1) | EA010159B1 (no) |
HR (1) | HRP20050721A2 (no) |
MX (1) | MXPA05008815A (no) |
NO (1) | NO20054292L (no) |
NZ (1) | NZ541750A (no) |
PL (1) | PL379983A1 (no) |
WO (1) | WO2004073653A2 (no) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2448956C (en) * | 2001-05-30 | 2017-10-03 | Genentech, Inc. | Anti-ngf antibodies for the treatment of various disorders |
CA2500901A1 (en) * | 2002-10-04 | 2004-04-22 | Rinat Neuroscience Corp. | Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists |
UA80447C2 (en) * | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
AU2003304238A1 (en) * | 2002-10-08 | 2005-01-13 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same |
MXPA05003502A (es) * | 2002-10-08 | 2005-09-30 | Rinat Neuroscience Corp | Metodo para tratar dolor post-quirurgico al administrar un antagonista del factor de crecimiento de nervios y composiciones que contienen el mismo. |
NZ540730A (en) | 2002-12-24 | 2010-09-30 | Rinat Neuroscience Corp | Anti-NGF antibodies and methods using same |
US7569364B2 (en) * | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
ATE491444T1 (de) | 2003-02-19 | 2011-01-15 | Rinat Neuroscience Corp | Verfahren zur behandlung von schmerzen durch verabreichung eines nervenwachstumsfaktor- antagonisten und eines nsaid und diese enthaltende zusammensetzung |
ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
KR101504729B1 (ko) | 2004-04-07 | 2015-03-19 | 리나트 뉴로사이언스 코프. | 신경성장인자 길항제의 투여에 의한 골암 통증 치료용 약학적 조성물 |
ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
ITRM20050332A1 (it) * | 2005-06-24 | 2006-12-25 | Lay Line Genomics Spa | Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore. |
EP1945668A4 (en) * | 2005-08-15 | 2009-07-22 | Arana Therapeutics Ltd | SYNTHETIC ANTIBODIES WITH FRAMEWORK REGIONS OF NEUWELTPRIMATEN |
EP1933714B1 (en) | 2005-09-21 | 2020-03-18 | The Regents of The University of California | Systems and compositions for local imaging and treatment of pain |
CN101410012A (zh) * | 2006-03-28 | 2009-04-15 | 杰佛林制药公司 | 低剂量的非甾体抗炎药和β-环糊精的制剂 |
WO2007112272A2 (en) * | 2006-03-28 | 2007-10-04 | Javelin Pharmaceuticals, Inc. | Formulations of low dose diclofenac and beta-cyclodextrin |
JP5577098B2 (ja) * | 2006-12-21 | 2014-08-20 | アムジエン・インコーポレーテツド | ポリペプチドを含有する安定な緩衝化された製剤 |
US8603950B2 (en) | 2007-02-20 | 2013-12-10 | Anaptysbio, Inc. | Methods of generating libraries and uses thereof |
PT2187964E (pt) | 2007-08-10 | 2015-01-14 | Regeneron Pharma | Anticorpos humanos de elevada afinidade para o factor de crescimento neural humano |
US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
EP2354225B1 (en) | 2008-09-24 | 2015-04-22 | Ribomic Inc. | Aptamer for ngf and use thereof |
PT2405748T (pt) * | 2009-03-12 | 2018-11-23 | Cumberland Pharmaceuticals Inc | Administração de ibuprofeno intravenoso |
PT2448970E (pt) * | 2009-05-04 | 2014-10-20 | Abbvie Res B V | Anticorpos contra factor de crescimento nervoso (ngf) com estabilidade in vivo melhorada |
US8871810B2 (en) | 2009-07-15 | 2014-10-28 | Cumberland Pharmaceuticals Inc. | Treating critically ill patients with intravenous ibuprofen |
CA2785056A1 (en) | 2009-12-22 | 2011-07-21 | Pondera Biotechnologies, LLC | Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications |
AU2011230388B2 (en) | 2010-03-24 | 2016-09-08 | Fujimoto Pharmaceutical Corporation | Aptamer for NGF and use thereof |
RS63063B1 (sr) | 2010-08-19 | 2022-04-29 | Zoetis Belgium S A | Anti-ngf antitela i njihova upotreba |
US9067988B2 (en) * | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
JP6190723B2 (ja) | 2010-12-01 | 2017-08-30 | アルダーバイオ ホールディングス エルエルシー | 抗ngf組成物およびその使用 |
GB201114858D0 (en) * | 2011-08-29 | 2011-10-12 | Nvip Pty Ltd | Anti-nerve growth factor antibodies and methods of using the same |
US9580496B2 (en) * | 2011-05-06 | 2017-02-28 | Nexvet Australia Pty Ltd | Therapeutic canine immunoglobulins and methods of using same |
KR101783929B1 (ko) | 2011-05-06 | 2017-10-11 | 넥스베트 오스트레일리아 피티와이 리미티드 | 항신경성 성장 인자 항체 및 그의 제조방법과 이용방법 |
US9072661B2 (en) | 2012-03-16 | 2015-07-07 | Cumberland Pharmaceuticals Inc. | Injectable ibuprofen formulation |
US9072710B2 (en) | 2012-03-16 | 2015-07-07 | Cumberland Pharmaceuticals Inc. | Injectable ibuprofen formulation |
US9617334B2 (en) | 2012-06-06 | 2017-04-11 | Zoetis Services Llc | Caninized anti-NGF antibodies and methods thereof |
CN110074880B (zh) | 2013-03-14 | 2022-04-29 | Bio Dg股份有限公司 | 包含具有增强的降解速率的生物可降解的合金的可植入的医疗装置 |
WO2018089467A1 (en) * | 2016-11-09 | 2018-05-17 | Beth Israel Deaconess Medical Center, Inc. | Methods for reducing recurrence of tumors |
AU2019234213A1 (en) | 2018-03-12 | 2020-09-03 | Zoetis Services Llc | Anti-NGF antibodies and methods thereof |
AU2019250128A1 (en) | 2018-10-15 | 2020-04-30 | Avent Inc. | Compositions, systems, kits, and methods for neural ablation |
Family Cites Families (137)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
SU975016A1 (ru) | 1979-12-17 | 1982-11-23 | Московский научно-исследовательский онкологический институт им.П.А.Герцена | Болеутол ющее средство |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
WO1995013796A1 (en) | 1993-11-16 | 1995-05-26 | Depotech Corporation | Vesicles with controlled release of actives |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
AU3418389A (en) | 1988-03-28 | 1989-10-16 | Regents Of The University Of California, The | Nerve growth factor peptides |
US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP0832980B1 (en) | 1989-01-23 | 2002-06-19 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
WO1990011092A1 (en) | 1989-03-21 | 1990-10-04 | Vical, Inc. | Expression of exogenous polynucleotide sequences in a vertebrate |
US6673776B1 (en) | 1989-03-21 | 2004-01-06 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human |
WO1991002805A2 (en) | 1989-08-18 | 1991-03-07 | Viagene, Inc. | Recombinant retroviruses delivering vector constructs to target cells |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
US5656435A (en) | 1989-08-28 | 1997-08-12 | Takeda Chemical Industries, Ltd. | Antibodies to peptides having NGF-like activity, said antibodies having no substantial cross-reactivity with NGF, and use thereof |
DE69031726T2 (de) | 1989-08-28 | 1998-03-12 | Takeda Chemical Industries Ltd | Antikörper, ihre Herstellung und Verwendung |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
NZ237464A (en) | 1990-03-21 | 1995-02-24 | Depotech Corp | Liposomes with at least two separate chambers encapsulating two separate biologically active substances |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5147294A (en) | 1990-10-01 | 1992-09-15 | Trustees Of Boston University | Therapeutic method for reducing chronic pain in a living subject |
FR2669336B1 (fr) | 1990-11-20 | 1993-01-22 | Adir | Nouveaux derives d'oxazolo pyridines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent. |
EP0564531B1 (en) | 1990-12-03 | 1998-03-25 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
US5278299A (en) | 1991-03-18 | 1994-01-11 | Scripps Clinic And Research Foundation | Method and composition for synthesizing sialylated glycosyl compounds |
JPH04315209A (ja) * | 1991-04-12 | 1992-11-06 | Mitsubishi Electric Corp | マイクロコンピュータ |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
WO1993003769A1 (en) | 1991-08-20 | 1993-03-04 | THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES | Adenovirus mediated transfer of genes to the gastrointestinal tract |
AU669124B2 (en) | 1991-09-18 | 1996-05-30 | Kyowa Hakko Kirin Co., Ltd. | Process for producing humanized chimera antibody |
DK0605522T3 (da) * | 1991-09-23 | 2000-01-17 | Medical Res Council | Fremgangsmåde til fremstilling af humaniserede antistoffer |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
WO1993010260A1 (en) | 1991-11-21 | 1993-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases |
GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1993025234A1 (en) | 1992-06-08 | 1993-12-23 | The Regents Of The University Of California | Methods and compositions for targeting specific tissue |
US5342942A (en) | 1992-06-09 | 1994-08-30 | Warner-Lambert Company | Pyrazoloquinazolone derivatives as neurotrophic agents |
JPH09507741A (ja) | 1992-06-10 | 1997-08-12 | アメリカ合衆国 | ヒト血清による不活性化に耐性のあるベクター粒子 |
GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
EP0673431A1 (en) | 1992-12-03 | 1995-09-27 | Genzyme Corporation | Gene therapy for cystic fibrosis |
US5604260A (en) | 1992-12-11 | 1997-02-18 | Merck Frosst Canada Inc. | 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 |
US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5409944A (en) | 1993-03-12 | 1995-04-25 | Merck Frosst Canada, Inc. | Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase |
PT695169E (pt) | 1993-04-22 | 2003-04-30 | Skyepharma Inc | Lipossomas multivesiculares de ciclodextrina encapsulando compostos farmacologicos e metodos para a sua utilizacao |
US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
JP3532566B2 (ja) | 1993-06-24 | 2004-05-31 | エル. グラハム,フランク | 遺伝子治療のためのアデノウイルスベクター |
US5436265A (en) | 1993-11-12 | 1995-07-25 | Merck Frosst Canada, Inc. | 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents |
US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
DE69435233D1 (de) | 1993-09-15 | 2009-10-08 | Novartis Vaccines & Diagnostic | Rekombinante Alphavirus Vektoren |
ATE437232T1 (de) | 1993-10-25 | 2009-08-15 | Canji Inc | Rekombinanter adenoviren-vektor und verfahren zur verwendung |
WO1995014930A1 (en) | 1993-11-23 | 1995-06-01 | Genentech, Inc. | Kinase receptor activation assay |
AU697142B2 (en) | 1993-11-23 | 1998-10-01 | Genentech Inc. | Protein tyrosine kinases named Rse |
GB9402331D0 (en) | 1994-02-07 | 1994-03-30 | Univ Mcgill | Nerve growth factor structural analogs and their uses |
US5877016A (en) | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
US5844092A (en) | 1994-03-18 | 1998-12-01 | Genentech, Inc. | Human TRK receptors and neurotrophic factor inhibitors |
US6436908B1 (en) | 1995-05-30 | 2002-08-20 | Duke University | Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function |
ATE381624T1 (de) | 1994-05-09 | 2008-01-15 | Oxford Biomedica Ltd | Retrovirale vektoren mit verminderter rekombinationsrate |
US6291247B1 (en) | 1994-05-11 | 2001-09-18 | Queen's University At Kingston | Methods of screening for factors that disrupt neurotrophin conformation and reduce neurotrophin biological activity |
US5475995A (en) | 1994-05-16 | 1995-12-19 | Livingston; George G. | Truck spare tire locking rod |
GB9514160D0 (en) | 1994-07-25 | 1995-09-13 | Zeneca Ltd | Aromatic compounds |
US5616601A (en) | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
US5521213A (en) | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
US5593994A (en) | 1994-09-29 | 1997-01-14 | The Dupont Merck Pharmaceutical Company | Prostaglandin synthase inhibitors |
AU4594996A (en) | 1994-11-30 | 1996-06-19 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
US5552422A (en) | 1995-01-11 | 1996-09-03 | Merck Frosst Canada, Inc. | Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents |
US5604253A (en) | 1995-05-22 | 1997-02-18 | Merck Frosst Canada, Inc. | N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors |
US5639780A (en) | 1995-05-22 | 1997-06-17 | Merck Frosst Canada, Inc. | N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors |
US5510368A (en) | 1995-05-22 | 1996-04-23 | Merck Frosst Canada, Inc. | N-benzyl-3-indoleacetic acids as antiinflammatory drugs |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
WO1997015593A1 (en) | 1995-10-25 | 1997-05-01 | Queen's University At Kingston | Neurotrophin antagonists |
GB9525180D0 (en) | 1995-12-08 | 1996-02-07 | Univ Mcgill | Design of hormone-like antibodies with agonistic and antagonistic fuctions |
DE69739286D1 (de) | 1996-05-06 | 2009-04-16 | Oxford Biomedica Ltd | Rekombinationsunfähige retrovirale vektoren |
UA67725C2 (en) | 1996-06-03 | 2004-07-15 | Cephalon Inc | K-252a derivatives and a method for improvement of functioning and cell survival enhancement |
GB9616105D0 (en) | 1996-07-31 | 1996-09-11 | Univ Kingston | TrkA binding site of NGF |
CA2268450C (en) | 1996-10-21 | 2008-08-05 | Allelix Biopharmaceuticals, Inc. | Neurotrophin antagonist compositions |
US6284794B1 (en) | 1996-11-05 | 2001-09-04 | Head Explorer Aps | Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase |
DE19732928C2 (de) | 1997-07-31 | 2000-05-18 | Gruenenthal Gmbh | Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel |
US6376471B1 (en) | 1997-10-10 | 2002-04-23 | Johns Hopkins University | Gene delivery compositions and methods |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
US6127401A (en) | 1998-06-05 | 2000-10-03 | Cephalon, Inc. | Bridged indenopyrrolocarbazoles |
WO2000053211A2 (en) | 1999-03-09 | 2000-09-14 | University Of Southern California | Method of promoting myocyte proliferation and myocardial tissue repair |
US6468990B1 (en) | 1999-05-17 | 2002-10-22 | Queen's University At Kingston | Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
US6492380B1 (en) | 1999-05-17 | 2002-12-10 | Queen's University At Kingston | Method of inhibiting neurotrophin-receptor binding |
IT1306704B1 (it) | 1999-05-26 | 2001-10-02 | Sirs Societa Italiana Per La R | Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf. |
US6399780B1 (en) | 1999-08-20 | 2002-06-04 | Cephalon, Inc. | Isomeric fused pyrrolocarbazoles and isoindolones |
US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
EP1235842A4 (en) | 1999-10-15 | 2003-04-23 | Univ Massachusetts | GENESIS OF THE RNA INTERFERENCE PATH AS AID OF TARGETED GENTIAN INTERFERENCE |
US6548062B2 (en) | 2000-02-29 | 2003-04-15 | Cephalon, Inc. | Method of treating cancer with anti-neurotrophin agents |
FR2807660A1 (fr) | 2000-04-13 | 2001-10-19 | Warner Lambert Co | Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques |
CA2410947A1 (en) | 2000-05-30 | 2001-12-06 | Johnson & Johnson Research Pty Limited | Methods for mediating gene suppresion by using factors that enhance rnai |
US7022484B2 (en) | 2000-06-08 | 2006-04-04 | Board Of Regents, The University Of Texas System | Methods for treating neuropathological states and neurogenic inflammatory states and methods for identifying compounds useful therein |
GB0020504D0 (en) | 2000-08-18 | 2000-10-11 | Univ Bristol | Therapeutic method |
US6630500B2 (en) | 2000-08-25 | 2003-10-07 | Cephalon, Inc. | Selected fused pyrrolocarbazoles |
AU2001288374A1 (en) | 2000-09-01 | 2002-03-22 | Glaxo Group Limited | Substituted oxindole derivatives as tyrosine kinase inhibitors |
JP4095895B2 (ja) | 2000-12-01 | 2008-06-04 | マックス−プランク−ゲゼルシャフト ツール フォーデルング デル ヴィッセンシャフテン エー.ヴェー. | Rna干渉を媒介する短鎖rna分子 |
US7128825B2 (en) * | 2001-03-14 | 2006-10-31 | Applied Materials, Inc. | Method and composition for polishing a substrate |
CA2448956C (en) | 2001-05-30 | 2017-10-03 | Genentech, Inc. | Anti-ngf antibodies for the treatment of various disorders |
WO2002102232A2 (en) | 2001-06-14 | 2002-12-27 | The Regents Of The University Of California | A novel signaling pathway for the production of inflammatory pain and neuropathy |
EP1434576A4 (en) | 2001-09-13 | 2006-03-29 | Kenneth E Miller | METHOD FOR RELIEVING PAIN |
US20040038874A1 (en) | 2002-08-22 | 2004-02-26 | Osemwota Omoigui | Method of treatment of persistent pain |
US6919426B2 (en) | 2002-09-19 | 2005-07-19 | Amgen Inc. | Peptides and related molecules that modulate nerve growth factor activity |
AU2003299071A1 (en) | 2002-09-26 | 2004-04-19 | L'oreal | Glossy non-transfer composition comprising a sequenced polymer |
CA2500901A1 (en) | 2002-10-04 | 2004-04-22 | Rinat Neuroscience Corp. | Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists |
AU2003304238A1 (en) | 2002-10-08 | 2005-01-13 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same |
MXPA05003502A (es) * | 2002-10-08 | 2005-09-30 | Rinat Neuroscience Corp | Metodo para tratar dolor post-quirurgico al administrar un antagonista del factor de crecimiento de nervios y composiciones que contienen el mismo. |
UA80447C2 (en) * | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
NZ540730A (en) | 2002-12-24 | 2010-09-30 | Rinat Neuroscience Corp | Anti-NGF antibodies and methods using same |
WO2004065560A2 (en) | 2003-01-18 | 2004-08-05 | Rinat Neuroscience Corp. | Methods of screening for modulators of nerve growth factor |
ATE491444T1 (de) | 2003-02-19 | 2011-01-15 | Rinat Neuroscience Corp | Verfahren zur behandlung von schmerzen durch verabreichung eines nervenwachstumsfaktor- antagonisten und eines nsaid und diese enthaltende zusammensetzung |
NZ599196A (en) | 2003-07-15 | 2014-01-31 | Amgen Inc | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors |
KR101504729B1 (ko) | 2004-04-07 | 2015-03-19 | 리나트 뉴로사이언스 코프. | 신경성장인자 길항제의 투여에 의한 골암 통증 치료용 약학적 조성물 |
KR101298383B1 (ko) | 2005-01-24 | 2013-08-20 | 엘란 파마 인터내셔널 리미티드 | Ngf에 대한 특이적 결합 멤버 |
-
2004
- 2004-02-19 AT AT04712940T patent/ATE491444T1/de not_active IP Right Cessation
- 2004-02-19 JP JP2006503765A patent/JP2006525960A/ja not_active Withdrawn
- 2004-02-19 MX MXPA05008815A patent/MXPA05008815A/es not_active Application Discontinuation
- 2004-02-19 WO PCT/US2004/005162 patent/WO2004073653A2/en active Application Filing
- 2004-02-19 US US10/783,730 patent/US7655231B2/en not_active Expired - Fee Related
- 2004-02-19 NZ NZ541750A patent/NZ541750A/en unknown
- 2004-02-19 CA CA002516454A patent/CA2516454A1/en not_active Abandoned
- 2004-02-19 EA EA200501319A patent/EA010159B1/ru unknown
- 2004-02-19 BR BR0407375-4A patent/BRPI0407375A/pt not_active IP Right Cessation
- 2004-02-19 PL PL379983A patent/PL379983A1/pl not_active Application Discontinuation
- 2004-02-19 KR KR1020057015300A patent/KR20050111598A/ko active Search and Examination
- 2004-02-19 AU AU2004213044A patent/AU2004213044A1/en not_active Abandoned
- 2004-02-19 EP EP10151127A patent/EP2191846A1/en not_active Withdrawn
- 2004-02-19 EP EP04712940A patent/EP1594441B1/en not_active Expired - Lifetime
- 2004-02-19 DE DE602004030535T patent/DE602004030535D1/de not_active Expired - Lifetime
-
2005
- 2005-08-18 HR HR20050721A patent/HRP20050721A2/xx not_active Application Discontinuation
- 2005-09-16 NO NO20054292A patent/NO20054292L/no not_active Application Discontinuation
-
2009
- 2009-12-22 US US12/644,087 patent/US8034346B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US8034346B2 (en) | 2011-10-11 |
WO2004073653A8 (en) | 2004-12-02 |
WO2004073653A3 (en) | 2006-06-08 |
DE602004030535D1 (de) | 2011-01-27 |
KR20050111598A (ko) | 2005-11-25 |
AU2004213044A1 (en) | 2004-09-02 |
EP2191846A1 (en) | 2010-06-02 |
JP2006525960A (ja) | 2006-11-16 |
ATE491444T1 (de) | 2011-01-15 |
MXPA05008815A (es) | 2006-05-25 |
NZ541750A (en) | 2008-11-28 |
US20100143355A1 (en) | 2010-06-10 |
CA2516454A1 (en) | 2004-09-02 |
US20040253244A1 (en) | 2004-12-16 |
PL379983A1 (pl) | 2006-11-27 |
WO2004073653A2 (en) | 2004-09-02 |
EA200501319A1 (ru) | 2006-08-25 |
EP1594441B1 (en) | 2010-12-15 |
EP1594441A2 (en) | 2005-11-16 |
EA010159B1 (ru) | 2008-06-30 |
EP1594441A4 (en) | 2007-09-26 |
HRP20050721A2 (en) | 2007-03-31 |
BRPI0407375A (pt) | 2006-02-07 |
US7655231B2 (en) | 2010-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20054292L (no) | Fremgangsmate for behandling av smerte ved administrering av en nervevekstfaktorantagonist og NSAID og preparat inneholdende dette | |
NO20052221D0 (no) | Fremgangsmater for behandling av smerte ved administering av en nervevekstfaktoragonist og et opioid smertestillende middel og preparater inneholdende dette | |
NO20072352L (no) | Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet | |
CY1116377T1 (el) | Αναστολεις της ανθρωπινης πρωτεϊνικης φωσφατασης της τυροσινης και μεθοδοι χρησης | |
NO20072199L (no) | Trombopoietinaktivitetsmodulerende forbindelser og fremgangsmater | |
NO20070091L (no) | Sukkerbelegg og fremgangsmate for dette | |
NO20083220L (no) | Heterocykliske derivater som modulatorer for ionekanaler | |
DK1934174T3 (da) | Azetidiner som MEK inhibitorer til behandling af proliferative sygdomme | |
NO20075693L (no) | Modulerende forbindelser av indolamin-2,3-dioksygenase og fremgangsmater for anvendelse av samme | |
NO20085131L (no) | Lyofiliserte preparater av anti-EGFR-antistoffer | |
NO20064976L (no) | Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser | |
NO20061080L (no) | Kondenserte pyramidinforbindelser som inhibitorer av spenningsstyrte ionekanaler | |
NO20052888L (no) | Diamintriazoler anvendelige som inhibitorer av proteinkinaser | |
EA200900802A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
IL175158A0 (en) | Tocopherol-modified therapeutic drug compounds | |
NO20055832L (no) | Fremstilling og anvendelse av arylalkylsyrederivater for behandling av fedme | |
NO20073628L (no) | Pyridoner som er nyttige som inhibitorer av kinaser | |
DK1651161T3 (da) | Farmaceutiske præparater og fremgangsmåder til at fremme sårheling | |
EA200600078A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
NO20070723L (no) | Progesteron reseptormodulatorer inneholdende pyrrol-oksindolderivater og deres anvendelse | |
BRPI0309665B8 (pt) | método para analisar uma preparação de alfagalactosidase a | |
NO20090157L (no) | Tienpyrimidiner anvendelige som modulatorer av ionekanaler | |
TW200616612A (en) | Method for the teatment of polycystic kidney disease field of invention | |
NO20060392L (no) | Kombinasjon av SRC kinase inhibitorer kemoterapeutiske midler for behandling av proliferative sykdommer | |
EA200800546A1 (ru) | Бензимидазолтиофеновые соединения в качестве ингибиторов polo-подобных киназ (plk) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |